Bone Marrow-Derived Mononuclear Cell Transplants Decrease Retinal Gliosis in Two Animal Models of Inherited...

Area of Science:

• Ophthalmology
• Stem Cell Therapy
• Neuroscience

Background:

• Inherited photoreceptor degenerations cause blindness and are currently untreatable.
• Adult human bone-marrow-derived mononuclear stem cells (hBM-MSCs) are being explored for therapeutic potential in degenerative diseases.

Purpose of the Study:

• To investigate the safety, integration, and potential rescue effects of hBM-MSC transplantation in animal models of inherited photoreceptor degeneration.
• To evaluate the impact of hBM-MSC transplantation on photoreceptor survival and retinal cellular changes.

Main Methods:

• Intravitreal and subretinal injections of hBM-MSCs were performed in P23H-1 and Royal College of Surgeons (RCS) rats.
• Immunosuppression was administered prior to and throughout the study.
• Retinal tissues were analyzed at multiple time points (7, 15, 30, 60 days) using immunodetection for various cell types.

Main Results:

• hBM-MSC transplantation showed no local adverse effects.
• Transplanted cells (CD45+) were detected for up to 15 days in the vitreous or subretinal space.
• No significant increase in photoreceptor survival or decrease in microglial cell numbers was observed.
• A decrease in glial fibrillary acidic protein (GFAP) immunoreactivity, indicating reduced retinal gliosis, was noted.

Conclusions:

• Intravitreal or subretinal hBM-MSC injection in these rat models decreases retinal gliosis.
• The treatment did not demonstrate short-term photoreceptor neuroprotective effects.
• Further investigation is warranted to explore the potential therapeutic effects of hBM-MSCs in inherited retinal degenerations.